FindTrial
Sign In

Ayurvedic Management For Skin Disease Dadru( Tinea)

An Open Randomised Control Clinical Trial Of Dadruhar Lepa In Comparison With Terbinafine In The Management Of Dadru

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/05/033606
Enrollment
60
Registered
2021-05-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue

Interventions

Intervention1: Dadruhar Lepa: Content and preparation of Dadruhar Lepa - Laksha ,Suntha, Marich , Pippali, Prapunnat , shreeveshatk,kushtha,siddhartak,haridra,mulak,takra - Each 1 Part is taken . All

Sponsors

Dr Samruddhi P Gujarathi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects of either gender Subjects with age 18to 70 yrs of age Subjects presenting either any all classical signs and symptoms of Dadru like itching(kandu),erythema(raga),Papules(pidika)

Exclusion criteria

Exclusion criteria: Subjects having any acute systemic illness ,uncontrolled DM ( HbA1C > 7.5) etc . Subjects having skin disorders other than Dadru . K/c/o immunocompromising condition or on imunosuppresive drugs.

Design outcomes

Primary

MeasureTime frame
Dadruhar Lepa is more effective in the management of Dadru than Terbinafine .Timepoint: Followup - Every Patient Will be followed every week for 4 week—

Secondary

MeasureTime frame
The effect of Dadruhar lepa is pharmacoequivalent to that of TerbinafineTimepoint: Followup - Every Patient Will be followed every week for 4 week—

Countries

India

Contacts

Public ContactDr Mahesh Pandey

Y.M.T Ayurvedic Medical College , Kharghar

drpandeymahesh@gmail.com9820006082

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026